Physician profile
Peyton N Travis
NPI 1245948405
$4,813.44
in general payments reported to CMS, 2019-2025
23 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,371 · 2024: $1,817 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,813.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $791.87 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $749.67 | 2023-2025 | |
| Novo Nordisk INC | $723.62 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $715.47 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.64 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $242.58 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Pfizer INC. | $185.78 | 2024-2025 | |
| Abbott Laboratories | $179.44 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $173.87 | 2023-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $124.91 | 2024 | Spravato |
| Exact Sciences Corporation | $116.91 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $83.70 | 2023-2025 | Apretude |
| Gilead Sciences, INC. | $81.01 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $75.32 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $73.67 | 2023-2024 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $63.43 | 2025 | Auvelity |
| Astellas Pharma US INC | $28.09 | 2025 | Veozah |
| Dexcom, INC. | $26.78 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $24.33 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $22.48 | 2023 | Belsomra, Steglatro |
| Dynavax Technologies Corporation | $18.22 | 2023 | Heplisav-B |
| Currax Pharmaceuticals LLC | $17.46 | 2024 | Contrave |
| Vivus LLC | $17.19 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyton Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.